tbuckley/cabot-search huggingface dataset:
Soundings: The Full English
Authors: Des Spence
Journal: BMJ (2006)

Screaming, shouting, and tears—so begins the usual misery of October half term holiday. Mistakenly you decide to fly at 4 am, with four children, from an airport a drive of four hours away, and with a flight time of four hours. The Greek island roads are slower and scarier than Euro Disney rides, but eventually you arrive at the villa. That night, sweating and to the buzz of mosquitoes, you start the next journey—the guilt trip: the cheap flights, the ozone layer, global warming, the Albanian cleaners, spoiling your children, and your colleagues buckling with your work back home.

The Union Jack flutters over our resort—British in all but sovereignty. British soap operas on in all the bars, tabloid newspapers, football shirts, and baked beans. Restaurants advertise with long faded Polaroid snaps our cultural zenith “The Full English.” Breakfast for three euros—eggs, sausages, bacon, fried bread, beans, toast, jam, tea—normally with a beer.

Apparently we are the most obese nation in Europe, and on the beaches of Greece this is obvious. It is like a scene from The Full Monty. It is not the diabetes, the arthritis, heart disease, nor premature death that I have an issue with. It is the poverty of existence and utter emotional misery that obesity inflicts on people's lives.

We doctors, as ever distracted by the near ground of largely irrelevant “risk factors,” haven't noticed that the landscape and weather of life has completely changed. Wealth and consumerism have polluted and poisoned our lives with “convenience”—reducing many people to little more than passive spectators of life. Obesity is the single most important public health challenge. Don't think that clinical medicine, with its pills, clinics, calipers, and surgical bands, can help—these are merely a distraction.

The once heroic public health doctors now crouch in the wings mumbling incomprehensibly about a bird flu pandemic. But it is time for a comeback and for England's chief medical officer, Liam Donaldson, to get his knuckle dusters out. What we need is a Victorian style renaissance in the structure of our everyday lives. The solutions are simple but not convenient—limit car use, encourage cycling and walking, tax processed foods, discount fresh foods, and rediscover the importance of exercise in all its forms.

My mosquito bites are fading, but not my memory. I am going to start cycling to work because I want out of this Greek tragedy.
Gaseous and Particulate Content of Laser Hair Removal Plume
Authors: Gary S. Chuang, William Farinelli, David C. Christiani, Robert F. Herrick, Norman C. Y. Lee, Mathew M. Avram
Journal: JAMA Dermatology (2016)

Potentially harmful chemicals are released when tissues are vaporized. Laser hair removal (LHR) causes heating and often vaporization of hairs, producing both a signature malodorous plume and visible particulates.To characterize the chemical composition and quantify the ultrafine particle content of the plume generated during LHR.In the laser center of a large academic hospital, discarded terminal hairs from the trunk and extremities were collected from 2 adult volunteers. The hair samples were sealed in glass gas chromatography chambers and treated with a laser. The laser plume was analyzed by gas chromatography-mass spectrometry (GC-MS). During LHR treatment, two 6-L negative pressure canisters were used to capture 30 seconds of laser plume, and a portable condensation particle counter was used to measure ultrafine particulates (<1 µm). Ultrafine particle concentrations were measured within the treatment room, within the waiting room, and outside the building.The chemical content of the laser plume was analyzed with GC-MS and screened for aerosolized toxins using Environmental Protection Agency-certified methods. The ambient concentration of ultrafine particles during LHR was measured by condensation particle counters.Analysis with GC-MS identified 377 chemical compounds. Sixty-two of these compounds, of which 13 are known or suspected carcinogens and more than 20 are known environmental toxins, exhibited strong absorption peaks. During LHR, the portable condensation particle counters documented an 8-fold increase compared with the ambient room baseline level of ultrafine particle concentrations (ambient room baseline, 15 300 particles per cubic centimeter [ppc]; LHR with smoke evacuator, 129 376 ppc), even when a smoke evacuator was in close proximity (5.0 cm) to the procedure site. When the smoke evacuator was turned off for 30 seconds, there was a more than 26-fold increase in particulate count compared with ambient baseline levels (ambient baseline, 15 300 ppc; LHR without smoke evacuator for 30 seconds, 435 888 ppc).These findings establish the concern that the burning-hair plume often present during LHR should be considered a biohazard, warranting the use of smoke evacuators, good ventilation, and respiratory protection, especially for health care workers with prolonged exposure to LHR plume.
Behavioral hyporeactivity to physostigmine in detoxified primary alcoholics
Authors: D S Janowsky, S C Risch, M Irwin, M A Schuckit
Journal: American Journal of Psychiatry (1989)

Changes in anergia/inhibition, mood, and pulse rate induced by intravenous physostigmine were significantly less pronounced in 26 patients with primary alcoholism than in 36 normal control subjects. These results suggest possible abnormalities in central cholinergic functioning in primary alcoholics.
Neuroendocrine and behavioral responses to intravenous m- chlorophenylpiperazine (mCPP) in depressed patients and healthy comparison subjects
Authors: A Anand, D S Charney, P L Delgado, C J McDougle, G R Heninger, L H Price
Journal: American Journal of Psychiatry (1994)

This double-blind study was undertaken to compare central serotonergic function in depressed patients and healthy comparison subjects by examining neuroendocrine and mood responses to intravenous infusion of the serotonin agonist m-chlorophenylpiperazine (mCPP).The participants were 20 drug-free patients with DSM-III-R major depression and 18 healty comparison subjects. After an overnight fast, the subjects received an intravenous infusion of mCPP, 0.1 mg/kg, or placebo saline. Blood was obtained for measurement of serum prolactin, growth hormone (GH), and cortisol. Visual analogue scales were used to assess mood.The depressed patients had a blunted GH response and felt less drowsy than the comparison subjects; prolactin, cortisol, and the remaining behavioral ratings showed no differences between the two groups.In light of findings with other provocative agents, the blunted GH response to mCPP may reflect a defect in GH production in depression and could be a marker of the depressed state. The lack of differences in the other neuroendocrine variables suggests that the functioning of postsynaptic serotonergic receptors responsive to mCPP may be relatively intact in depression.
Improving Communication About Serious Illness in Primary Care
Authors: Joshua R. Lakin, Susan D. Block, J. Andrew Billings, Luca A. Koritsanszky, Rebecca Cunningham, Lisa Wichmann, Doreen Harvey, Jan Lamey, Rachelle E. Bernacki
Journal: JAMA Internal Medicine (2016)

<h3>Importance</h3> The Institute of Medicine recently called for systematic improvements in clinician-led conversations about goals, values, and care preferences for patients with serious and life-threatening illnesses. Studies suggest that these conversations are associated with improved outcomes for patients and their families, enhanced clinician satisfaction, and lower health care costs; however, the role of primary care clinicians in driving conversations about goals and priorities in serious illness is not well defined. <h3>Objective</h3> To present a review of a structured search of the evidence base about communication in serious illness in primary care. <h3>Evidence Review</h3> MEDLINE was searched, via PubMed, on January 19, 2016, finding 911 articles; 126 articles were reviewed and selected titles were added from bibliography searches. <h3>Findings</h3> Review of the literature informed 2 major topic areas: the role of primary care in communication about serious illness and clinician barriers and system failures that interfere with effective communication. Literature regarding the role that primary care plays in communication focused primarily on the ambiguity about whether primary care clinicians or specialists are responsible for initiating conversations, the benefits of primary care clinicians and specialists conducting conversations, and the quantity and quality of discussions. Timely and effective communication about serious illness in primary care is hampered by key clinician barriers, which include deficits in knowledge, skills, and attitudes; discomfort with prognostication; and lack of clarity about the appropriate timing and initiation of conversations. Finally, system failures in coordination, documentation, feedback, and quality improvement contribute to lack of conversations. <h3>Conclusions and Relevance</h3> Clinician and system barriers will challenge primary care clinicians and institutions to meet the needs of patients with serious illness. Ensuring that conversations about goals and values occur at the appropriate time for seriously ill patients will require improved training, validation, and dissemination of patient selection tools, systems for conducting and revisiting conversations, accessible documentation, and incentives for measurement, feedback, and continuous improvement.
Tumor-Damaging Capacity of Plant Materials. IV. Conifers
Authors: Dorothea B. Fitzgerald, Morris Belkin, Marie D. Felix, Mary K. Carroll
Journal: JNCI Journal of the National Cancer Institute (1953)

Journal Article Tumor-Damaging Capacity of Plant Materials. IV. Conifers Get access Dorothea B. Fitzgerald, Dorothea B. Fitzgerald Search for other works by this author on: Oxford Academic PubMed Google Scholar Morris Belkin, Morris Belkin Search for other works by this author on: Oxford Academic PubMed Google Scholar Marie D. Felix, Marie D. Felix Search for other works by this author on: Oxford Academic PubMed Google Scholar Mary K. Carroll Mary K. Carroll Laboratory of Chemical Pharmacology, National Cancer Institute3Bethesda, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 13, Issue 4, February 1953, Pages 895–903, https://doi.org/10.1093/jnci/13.4.895 Published: 01 February 1953 Article history Received: 30 September 1952 Published: 01 February 1953
CD133 Is a Positive Marker Of Human Cord Blood-Derived CD34-Negative Hematopoietic Stem Cells
Authors: Masaya Takahashi, Yoshikazu Matsuoka, Keisuke Sumide, Ryusuke Nakatsuka, Tatsuya Fujioka, Hirao Kohno, Yutaka Sasaki, Kazuo Matsui, Hiroaki Asano, Kazunari Kaneko, Yoshiaki Sonoda
Journal: Blood (2013)
PD-030 Prospective non-interventional study to collect data on the use of bevacizumab and conventional chemotherapy for the treatment of previously untreated metastatic colorectal cancer in patient's ≥70 years
Authors: E. Van Cutsem, L. Decoster, G. Houbiers, B. Naessens, M. De Man, G. Lambrecht, E. Monsaert, V. Moons, P. Vergauwe, C. Kenis, H. Wildiers, L. Opstaele, E. Van De Walle, H. Prenen
Journal: Annals of Oncology (2016)
Moving pictures: Highlights 2016 open for submissions
Authors: Joanna Palmer, Zoë Mullan
Journal: The Lancet Global Health (2016)

Last autumn the image of a young Syrian boy lying dead on a Turkish beach highlighted the humanitarian plight of refugees and influenced public opinion. The photograph of Alan Kurdi spoke to people more powerfully than any words could have done. Photographs can move us, enrage us, challenge our ideas, and provoke us to action. Other pictures can bring joy and hope. In last year's Lancet Highlights photography competition, one of the winning images showed a 5-year-old boy in Zimbabwe looking in a mirror with rapt attention at his newly repaired cleft lip. These two pictures remind us how photographs capture a moment in a powerful and moving way. Images can highlight an important health issue and we invite readers to send us photographs for our annual photography competition, Highlights 2016. Whether your focus is local or global, we want you to send us photographs that surprise and move us by telling a story about health today. We are interested in photographs that capture any health issue in a thought-provoking way. As in previous years, The Lancet and The Lancet Global Health will run the competition together. Winning photographs will be published in The Lancet's final issue of 2016 and could be selected for the front cover of The Lancet Global Health. Each entry should be submitted with 300 accompanying words that put the image in context. Submissions should not have been previously published in print or online. If a person or patient is featured then you must obtain and keep written consent from the individual or, where this is not an option, their next of kin. Please complete the patient consent section of the author statements form while retaining copies of the signed forms. We also encourage you to submit any additional media to support your submission online, such as video or audio features. All photographs—colour or black and white—should be submitted through our online editorial submission system, along with the required text and any supporting material for online publication. Please select Lancet Photograph as the article type. If a digital camera is used please set it to the highest possible quality setting and submit images as JPEG files. If you are using a film camera please submit an 8 × 11 inch glossy print to The Lancet in the post. The entries will be judged by Lancet editors and there will be a £300 prize for winning entries. The deadline for entries is Nov 7, 2016. So share your photos with The Lancet and The Lancet Global Health: we look forward to looking at the stories you capture.
Patterns of Locoregional Relapses in Patients with Contemporarily Staged Stage III-N2 NSCLC Treated with Induction Chemotherapy and Resection: Implications for Postoperative Radiotherapy Target Volumes
Authors: Charlotte Billiet, Dirk De Ruysscher, Stéphanie Peeters, Herbert Decaluwé, Johan Vansteenkiste, Christophe Dooms, Christophe M. Deroose, Paul De Leyn, Marc Hendrikx, Paul Bulens, Cécile Le Péchoux, Jeroen Mebis
Journal: Journal of Thoracic Oncology (2016)
Surgery of the Heart and Great Vessels
Authors: Richard H. Sweet, J. Gordon Scannell
Journal: New England Journal of Medicine (1952)

The Great VesselsSome of the most important accomplishments of cardiovascular surgery are those having to do with the correction of congenital anomalies of the major vessels close to the heart and the creation of vascular shunts for the relief of certain cardiac anomalies. Although the technical problems involved in dealing with the vessels are simpler than those presented by the necessities of intracardiac surgery with a bloodless heart, it should be pointed out that every effort should be made to establish the diagnosis early in life so that the necessary corrective operation can be performed during childhood, before the . . .
Novel agents in the treatment of multiple myeloma: a review about the future
Authors: Leonard Naymagon, Maher Abdul-Hay
Journal: Journal of Hematology & Oncology (2016)

Multiple myeloma (MM) is a disease that affects plasma cells and can lead to devastating clinical features such as anemia, lytic bone lesions, hypercalcemia, and renal disease. An enhanced understanding of MM disease mechanisms has led to new more targeted treatments. There is now a plethora of treatments available for MM. In this review article, our aim is to discuss many of the novel agents that are being studied or have recently been approved for the treatment of MM. These agents include the following: immunomodulators (pomalidomide), proteasome inhibitors (carfilzomib, marizomib, ixazomib, oprozomib), alkylating agents (bendamustine), AKT inhibitors (afuresertib), BTK inhibitors (ibrutinib), CDK inhibitors (dinaciclib), histone deacetylase inhibitors (panobinostat, rocilinostat, vorinostat), IL-6 inhibitors (siltuximab), kinesin spindle protein inhibitors (filanesib), monoclonal antibodies (daratumumab, elotuzumab, indatuximab, SAR650984), and phosphoinositide 3-kinase (PI3K) inhibitors.
Diet and Exercise for Obese Patients With Heart Failure
Authors: Dimitrios Farmakis, John Parissis, Gerasimos Filippatos
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
AB0559 Reliability and Validity of The Turkish Translation of The Beliefs about Medicines Questionnaire (BMQ-T) in Patients with Behçet's Disease
Authors: M. Cinar, F.I. Cinar, C. Acikel, S. Yilmaz, M. Cakar, R. Horne, I. Simsek
Journal: Annals of the Rheumatic Diseases (2016)

The aim of this study was to evaluate the reliability and validity of the Turkish translation of the Beliefs about Medicines Questionnaire (BMQ-T, ©Prof. Rob Horne) for patients with Behçet's disease.This methodological study enrolled a sample of 125 patients. The scale was adapted to Turkish through a process including translation, comparison with versions in other languages, back translation, and pretesting. Construct validity was evaluated by factor analysis. Medication adherence evaluated as poor, moderate and good according to the Morisky Medication Adherence Scale (MMAS). BMQ-T scores compared along medication adherence status groups.In our study, as in the original scale, the factor analysis confirmed that the BMQ-T had a four-factor structure explaining 54.73% of the total variance. The BMQ-T had acceptable internal consistency (Cronbach's alpha coefficient: Specific Necessity=.812; Specific Concerns=.672; General Harm=.677; General Overuse=.656), adequate test-retest reliability (intraclass correlation coefficients: Specific Necessity=.715; Specific Concerns=.680; General Harm=.678; General Overuse=.327). Specific Necessity and Specific Concerns scores were significantly different between medication adherence status groups.The psychometric properties of the BMQ-T were consistent with those reported in the original study. The BMQ-T was found to be a valid and reliable tool for evaluating beliefs about medicines in patients with Behçet's disease.
Habitual Prescribing of Laxatives—It’s Time to Flush Outdated Protocols Down the Drain
Authors: Kanako Y. McKee, Eric Widera
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Influence of Sacubitril/Valsartan (LCZ696) on 30-Day Readmission After Heart Failure Hospitalization
Authors: Akshay S. Desai, Brian L. Claggett, Milton Packer, Michael R. Zile, Jean L. Rouleau, Karl Swedberg, Victor Shi, Martin Lefkowitz, Randall Starling, John Teerlink, John J.V. McMurray, Scott D. Solomon
Journal: Journal of the American College of Cardiology (2016)

Patients with heart failure (HF) are at high risk for hospital readmission in the first 30 days following HF hospitalization. This study sought to determine if treatment with sacubitril/valsartan (LCZ696) reduces rates of hospital readmission at 30-days following HF hospitalization compared with enalapril. We assessed the risk of 30-day readmission for any cause following investigator-reported hospitalizations for HF in the PARADIGM-HF trial, which randomized 8,399 participants with HF and reduced ejection fraction to treatment with LCZ696 or enalapril. Accounting for multiple hospitalizations per patient, there were 2,383 investigator-reported HF hospitalizations, of which 1,076 (45.2%) occurred in subjects assigned to LCZ696 and 1,307 (54.8%) occurred in subjects assigned to enalapril. Rates of readmission for any cause at 30 days were 17.8% in LCZ696-assigned subjects and 21.0% in enalapril-assigned subjects (odds ratio: 0.74; 95% confidence interval: 0.56 to 0.97; p = 0.031). Rates of readmission for HF at 30-days were also lower in subjects assigned to LCZ696 (9.7% vs. 13.4%; odds ratio: 0.62; 95% confidence interval: 0.45 to 0.87; p = 0.006). The reduction in both all-cause and HF readmissions with LCZ696 was maintained when the time window from discharge was extended to 60 days and in sensitivity analyses restricted to adjudicated HF hospitalizations. Compared with enalapril, treatment with LCZ696 reduces 30-day readmissions for any cause following discharge from HF hospitalization.